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Abstract 
Mutated in approximately 30% of human cancers, Ras GTPases are the most common 
drivers of oncogenesis and render tumors unresponsive to many standard therapies. Despite 
decades of research, no drugs directly targeting Ras are currently available. We have previously 
characterized a small protein antagonist of K-Ras, R11.1.6, and demonstrated its direct 
competition with Raf for Ras binding. Here we evaluate the effects of R11.1.6 on Ras signaling 
and cellular proliferation in a panel of human cancer cell lines. Through lentiviral transduction, 
we generated cell lines that constitutively or through induction with doxycycline express R11.1.6 
or a control protein YW1 and show specific binding by R11.1.6 to endogenous Ras through 
microscopy and co-immunoprecipitation experiments. Genetically-encoded intracellular 
expression of this high-affinity Ras antagonist, however, fails to measurably disrupt signaling 
through either the MAPK or PI3K pathway. Consistently, cellular proliferation was unaffected as 
well. To understand this lack of signaling inhibition, we quantified the number of molecules of 
R11.1.6 expressed by the inducible cell lines and developed a simple mathematical model 
describing the competitive binding of Ras by R11.1.6 and Raf. This model supports a potential 
mechanism for the lack of biological effects that we observed, suggesting stoichiometric and 
thermodynamic barriers that should be overcome in pharmacological efforts to directly compete 
with downstream effector proteins localized to membranes at very high effective concentrations.    
 
Introduction 
 K-Ras, H-Ras, and N-Ras are small GTPases that regulate key cellular processes 
including proliferation, migration, and survival. Nucleotide loading with either GTP or GDP 
defines the conformation of the switch I and switch II regions of Ras proteins and thereby their 
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state of activation (1-3). Active, GTP-bound Ras binds effector proteins including Raf (4) and 
PI3K (5) to initiate downstream signaling. Upon hydrolysis of GTP, Ras adopts an inactive, 
GDP-bound conformation that leads to termination of signaling.  
The Ras proteins comprise the most frequently mutated family of oncoproteins in all 
human cancers, including three of the most lethal forms, cancers of the lung, colon, and 
pancreas. Oncogenic Ras mutations, such as those at positions G12, G13, and Q61, impair 
intrinsic Ras activity (6), preventing GTP hydrolysis and resulting in constitutively active Ras 
capable of binding and signaling through downstream effector proteins. This leads to cell 
transformation, proliferation, and eventual migration and invasion (1-3). 
Given its high level of incidence across a large subset of cancer types and its well-
established role in tumor initiation, development, and progression, a large effort has been put 
forth in Ras inhibitor development. But despite decades of research and a renewed enthusiasm in 
recent years, no clinically approved drugs directly targeting Ras are currently available, primarily 
due to its disordered active site and smooth surface lacking well-defined drug-binding pockets 
(2,3). While small molecule inhibitors of Ras are low in their binding affinity and efficacy (3,7-
9), antagonists developed on protein scaffolds have greater ability to specifically and tightly 
interact with the smooth protein. Indeed, several protein-based Ras inhibitors have been 
developed (10-14) and have shown varying degrees of preclinical efficacy. 
We previously described a protein inhibitor R11.1.6, which was engineered on a scaffold 
based on the thermostable protein Sso7d (15) and was shown to exhibit preferential binding to 
K-Ras G12D over wild type (16). Extensive characterization of the binding interaction between 
R11.1.6 and K-Ras G12D indicated direct competition of R11.1.6 with downstream effector Raf, 
which led to inhibition of mutant K-Ras-induced signaling through the MAPK pathway in a 
on June 21, 2018. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 2, 2018; DOI: 10.1158/1535-7163.MCT-17-0645 
4 
 
model system. Here we evaluate the effects of R11.1.6-mediated endogenous K-Ras antagonism 
on a panel of human cancer cell lines and show an unexpected absence of signaling inhibition or 
reduction in cellular proliferation. To help understand this apparently contradictory outcome, we 
propose a simple mathematical model describing R11.1.6 binding of K-Ras in the presence of 
Raf, demonstrating that pharmacological efforts towards competitive Ras antagonism may be 
met with intrinsic challenges.   
 
Materials and Methods 
Reagents. Western blot antibodies were anti-vinculin (13901S), anti-pMEK1/2 (Ser217/221) 
(9121S), anti-MEK1/2 (9122S), anti-pERK p44/42 (Thr202/Tyr204) (9101S), anti-ERK (9102S), 
anti-pAKT (Ser473) (9271S), anti-AKT (9272S), anti-Ras (3339S), and anti-GFP (2555S) from 
Cell Signaling Technologies. Blots were detected with an HRP-conjugated secondary antibody 
(406401) from BioLegend. Wortmannin (W1628-1MG) (17) was purchased from Sigma, and 
ZSTK474 (18) was a kind gift from Dr. Forest White at MIT. 
 
Cell culture. HEK 293T (obtained from ATCC in 2016), A431 (obtained from ATCC in 2013), 
PA-TU-8902 (kind gift from Dr. Mandar Muzumdar, Jacks Lab, MIT, in 2017), and PA-TU-
8988T (kind gift from Dr. Mandar Muzumdar, Jacks Lab, MIT, in 2017) cells were cultured in 
DMEM. HT-29 (obtained from ATCC in 2013) and Calu-1 (obtained from ATCC in 2012) cells 
were cultured in McCoy’s 5A. HPAF-II (obtained from ATCC in 2015) and LS180 (obtained 
from ATCC in 2013) cells were cultured in EMEM. NCI-H23 (obtained from ATCC in 2012), 
SW48 WT, SW48 G12D, SW48 G12C, and SW48 G12V
 
(19) (all SW48 cell lines were kind 
gifts from the White lab, MIT, in 2016) were cultured in RPMI-1640. All media was 
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supplemented with 10% FBS (Life Technologies), 100 units/mL penicillin, and 100 μg/mL 
streptomycin (Life Technologies) and was purchased from ATCC and Life Technologies. Cell 
lines transduced to stably express R11.1.6, YW1, EGFP, or EGFP fusions of R11.1.6/YW1 were 
cultured in the media as indicated above. Cell lines transduced to express EGFP fusions of 
R11.1.6/YW1 under an inducible promoter were cultured in the media as indicated above, but 
without penicillin/streptomycin and with Tet System Approved FBS (Clontech) and 1-4 μg/mL 
puromycin (Life Technologies). All cell lines were maintained at 37°C and 5% CO2 and were 
authenticated by the manufacturer and tested for mycoplasma contamination to meet standard 
levels. Cell lines were passaged a minimum of five times and up to fifteen times before use. 
 
Subcloning. For constitutive expression, R11.1.6 and YW1 were cloned into lentiviral vector 
pLJM1-EGFP (Addgene plasmid #19319) using In-Fusion Cloning (Clontech) according to the 
manufacturer’s instructions. Cmyc-R11.1.6 and cmyc-YW1 were cloned into a modified version 
of the lentiviral vector pLJM1, in which protein expression is under the CMV promoter and 
EGFP under the PGK promoter, using In-Fusion Cloning (Clontech) according to the 
manufacturer’s instructions. For inducible expression, the sequences for EGFP-R11.1.6 and 
EGFP-YW1 were PCR amplified, digested with AgeI and NheI, and cloned into AgeI- and NheI- 
digested lentiviral pCW57.1 (Addgene plasmid #41393) vector. Cloning and DNA preparations 
were done using One Shot Stbl3 cells (Thermo Fisher Scientific). 
 
Lentivirus generation, transduction, and cell line selections. To generate VSV-G pseudotyped 
lentiviral particles using the pLJM1 and modified pLJM1 expression plasmids, second 
generation packaging plasmids were used. HEK 293T cells were transiently transfected in 10-cm 
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plates with pLJM1 or modified pLJM1 plasmids (into which had been cloned cmyc- or EGFP-
R11.1.6 or -YW1) and packaging plasmids using calcium phosphate. Approximately 24 hours 
following transfection, media containing virus particles was harvested and filtered through a 
0.45-um filter. To generate VSV-G pseudotyped lentiviral particles using the pCW57.1 
doxycycline-inducible expression plasmid, third generation packaging plasmids were used. HEK 
293T cells were transiently transfected in 10-cm plates with pCW57.1 plasmid (into which had 
been cloned EGFP-R11.1.6 or -YW1) and packaging plasmids using Fugene transfection reagent 
(Roche). After approximately 72 hours, media containing virus particles was harvested and 
centrifuged to remove cell debris. 
 To transduce cancer cell lines with pLJM1 lentiviral particles, cells to be infected were 
plated in 12-well plates and adhered overnight. Filtered virus harvested from the HEK 293T 
transient transfection was added at 1 mL/well and incubated for approximately 24 hours, after 
which virus-containing media was replaced with complete media as described above. To 
transduce cancer cell lines with pCW57.1 inducible lentiviral particles, cells to be infected were 
plated in 6-well plates and adhered overnight. Centrifuged virus harvested from the HEK 293T 
transient transfection was added at 0.5 mL/well to 1 mL/well complete media supplemented with 
polybrene (Sigma) at 5 ug/mL final concentration. Cells were transduced overnight at 37C. 
 To select successfully transduced cells with the pLJM1 viral particles, cells were sorted 
either once or twice based on EGFP expression using a FACS Aria IIU (BD Biosciences). 
Successfully transduced cells with the inducible pCW57.1 viral particles were selected using 
puromycin (Life Technologies) at 4 or 5 μg/mL final concentration. Selected cells were induced 
with doxycycline (Sigma) for 48 hours and read on a BD ACCURI C6 flow cytometer for EGFP 
expression. Flow cytometry data were analyzed using FlowJo software.   
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Quantitative PCR. Expression of R11.1.6 and YW1 in the pLJM1-based stable cell lines was 
verified using quantitative RT-PCR. RNA extraction was done using the NucleoSpiný RNA 
Midi kit (Clontech) according to the manufacturer’s instructions. RT-PCR and amplification 
were then performed using the QuantiTect SYBR Green RT-PCR kit (Qiagen) according to the 
manufacturer’s instructions, on a Roche Lightcycler 480 (Roche). The forward primer for 
R11.1.6/YW1 used was 5’- TTATTTCTGAAGAGGACTTGGGA-3’, and the reverse 5’- 
CCAACGGATTACCCACTTG-3’. Beta-actin was used as the housekeeping gene, with the 
forward primer of 5’- GTCTGCCTTGGTAGTGGATAATG-3’ and the reverse primer of 5’- 
TCGAGGACGCCCTATCATGG-3’. 
 
Fluorescence microscopy. Lentivirus-generated stable cell lines were plated on #1 glass cover 
slips (Chemglass) and adhered overnight. Approximately 24 hours after plating, cells were fixed 
with 4% paraformaldehyde for 10 minutes at room temperature and cover slips mounted with 
DAPI-containing mounting medium (Vectashield, Vector Laboratories) and dried overnight. 
Lentivirus-generated inducible stable cell lines were plated on #1 glass cover slips (Chemglass) 
and adhered overnight. Cells were induced with doxycycline (Sigma) at 2 μg/mL final 
concentration for 48 hours and then fixed with 4% paraformaldehyde for 10 minutes at room 
temperature and cover slips mounted with DAPI-containing mounting medium (Vectashield, 
Vector Laboratories) and dried overnight. Images were acquired at room temperature using a GE 
(Applied Precision) DeltaVision Spectris inverted Olympus X71 microscope with a 60x 
objective lens, captured with a Photometrics CoolSNAP HQ camera. SoftWoRx software was 
used for image acquisition and deconvolution. EGFP signal used the ex. 475/em. 528 filter set. 
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Cell signaling assay.  Lentivirus-generated stable cell lines were plated and adhered overnight, 
and then serum-starved overnight. Human EGF (Peprotech) was added at a final concentration of 
1 nM for 5 minutes, after which cells were washed on ice and lysed in protease inhibitor 
(cOmplete EDTA-free protease inhibitor cocktail, Roche) containing RIPA lysis buffer (Abcam). 
Lentivirus-generated inducible stable cell lines were plated and adhered overnight. Cells were 
induced with doxycycline (Sigma) at 125, 250, 500, 1000, or 2000 ng/mL final concentration for 
48 hours at 37C. Cells were washed on ice and lysed in protease inhibitor (cOmplete EDTA-
free protease inhibitor cocktail, Roche) containing RIPA lysis buffer (Abcam). Whole cell 
lysates were analyzed by western blot for activation of MEK, ERK, and/or AKT with 
phosphospecific antibodies.   
 
Proliferation assay. Stable cell line proliferation was measured using a WST-1-based 
colorimetric assay according to the manufacturer’s instructions (Roche). Cells were seeded in 
flat-bottom 96-well plates and incubated for 24, 48, or 72 hours at 37°C and 5% CO2, after 
which proliferation was determined. In some assays, PI3K inhibitors wortmannin (Sigma) or 
ZSTK474 (kind gift from the White lab, MIT) were added to cells for 24 hours, after which 
proliferation was determined. 
 
Clonogenic assay. Colony formation of the stable cell lines was evaluated by seeding cells at 
10,000 cells/well in 6-well plates and incubating them at 37°C and 5% CO2 until sufficiently 
large colonies (approximately 30-50 cells/colony) had formed, about 2-3 weeks. Once colonies 
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had formed, they were stained with a mixture of 6.0% glutaraldehyde (Sigma) and 0.5% crystal 
violet (Sigma) for 30 minutes at room temperature.   
 
Co-immunoprecipitation assay. Inducible stable cell lines were seeded in a 10-cm plate and 
adhered overnight, then induced with doxycycline (Sigma) at 3000 ng/mL final concentration for 
48 hours at 37C. Cells were washed on ice and lysed in protease inhibitor (cOmplete EDTA-
free protease inhibitor cocktail, Roche) containing lysis buffer (Life Technologies). Whole cell 
lysates were analyzed by western blot for total Ras and EGFP-R11.1.6/YW1. EGFP-
R11.1.6/YW1 were pulled down with anti-GFP beads (ChromoTek) and analyzed for co-
precipitation of Ras by western blotting. 
 
R11.1.6 quantification. To determine the number of EGFP-R11.1.6 molecules expressed in the 
inducible cell lines, we quantified both total mass of protein via western blot and fluorescence of 
EGFP via flow cytometry. Inducible stable cell lines were plated and adhered overnight, then 
induced with doxycycline (2000 ng/mL) for 48 hours at 37C. Cells were detached and counted, 
then washed and lysed in protease inhibitor (cOmplete EDTA-free protease inhibitor cocktail, 
Roche) containing RIPA lysis buffer (Abcam). Volumes of whole cell lysates equaling 50,000 
cells were analyzed by western blot with anti-GFP antibody (Cell Signaling Technologies), and 
the number of EGFP-R11.1.6 molecules per cell quantified using ImageJ software and a standard 
curve of recombinant GFP (Abcam). For quantification based on fluorescence, we utilized GFP 
flow cytometer calibration beads (Clontech) according to the manufacturer’s instructions. We 
plated and induced cell lines as above and read them on a BD ACCURI C6 flow cytometer for 
EGFP expression. Flow cytometry data were analyzed using FlowJo software.   
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Mathematical model. To model the degree of R11.1.6-mediated inhibition of complexes 
between K-Ras and Raf, we utilized a simple competitive binding inhibition model analogous to 
Michaelis-Menten-based derivations for competitive enzyme inhibitors (Fig. 3a and 
Supplementary Fig. S4). Rather than defining degree of inhibition of K-Ras by R11.1.6 as the 
fraction of K-Ras occupied by R11.1.6 (Supplementary Fig. S6a), we describe it as the number 
of K-Ras – Raf complexes that are prevented from forming by the presence of R11.1.6 
(Supplementary Fig. S6b-d). The number of R11.1.6 and Raf molecules in the cell was varied for 
a given number of K-Ras molecules in our simulations to obtain heatmaps as shown in Figure 3 
and Supplementary Figure S7. 
 
Results 
Intracellular expression of R11.1.6 has no apparent effect on cancer cell signaling and 
proliferation  
 Our recent engineering and characterization of R11.1.6, a novel protein antagonist which 
specifically binds mutant K-Ras G12D with single digit nanomolar affinity, showed a Ras 
binding epitope that is directly competitive with downstream effector Raf (16). Taking advantage 
of the ease of transfection of HEK 293T cells, we utilized this model system to show strong 
inhibition of signaling through the MAPK pathway in the presence of R11.1.6. To extend these 
findings to more relevant settings, we generated stable human cancer cell lines to constitutively 
express R11.1.6 or the control protein YW1 (in which two of the R11.1.6 paratope residues have 
been swapped to abrogate K-Ras binding (16)), either with an EGFP reporter or as EGFP fusions 
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(Supplementary Fig. S1a). We confirmed the expression of R11.1.6/YW1 in the EGFP reporter 
cell lines via quantitative RT-PCR (Supplementary Fig. S1b). 
 Human cancer cell lines HT-29 (colorectal, K-Ras WT), LS180 (colorectal, K-Ras 
G12D), and HPAF-II (pancreatic, K-Ras G12D) stably expressing EGFP fusions of R11.1.6 
show clear peripheral membrane staining, consistent with binding to Ras which localizes to the 
inner plasma membrane (Fig. 1a). Diffuse cytoplasmic fluorescence further indicates that 
sufficient excess of the EGFP-R11.1.6 fusion is present to avoid significant depletion upon 
binding to membrane-localized Ras. This membrane localization is not observed for control cell 
lines expressing EGFP-YW1 or EGFP only. We next investigated the effects of R11.1.6 
expression on endogenous Ras-driven signaling (Fig. 1b). Curiously, we observed no inhibition 
in either the MAPK or PI3K pathway, as evidenced by no changes in phosphorylation of MEK, 
ERK, or AKT (Ser473) in the presence of R11.1.6. This lack of signaling inhibition expectedly 
translated into unchanged levels of cellular proliferation (Fig. 1c), ability to form colonies 
(Supplementary Fig. S2a), and growth in soft agar. We thought that combination of R11.1.6-
mediated Ras antagonism and PI3K inhibition via small molecule inhibitors wortmannin and 
ZSTK474 may result in greater slowing of growth for the R11.1.6-expressing cell lines 
compared to controls, but found that across a range of concentrations of added inhibitor, there 
was no difference in proliferation between the cell lines attributable to R11.1.6 expression 
(Supplementary Fig. S2b).  
 We observed that cell lines transduced to stably express R11.1.6 maintained EGFP signal 
over the course of 30 days (Supplementary Fig. S2c), suggesting that presence of R11.1.6 does 
not affect proliferation even after considerable time has passed. Because cancer cells are known 
to develop resistance to chemotherapy and targeted therapy (20) and have been shown to 
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upregulate alternative pathways in response to targeted inhibitors (21), we hypothesized that the 
cell lines had circumvented R11.1.6 antagonism through amplification of other pathways. To 
mitigate the potential for resistance inherent in constitutive expression, we expanded our panel of 
human cancer cell lines (Table 1) and generated stable cell lines that express EGFP fusions of 
R11.1.6 or YW1 under an inducible promoter, so that only upon addition of doxycycline is there 
cytoplasmic expression. 
 Selected cell lines showed no leaky expression in the absence of doxycycline and 
induction of EGFP fused proteins at the highest doxycycline concentration (Supplementary Fig. 
S3). Consistent with our constitutively expressing stable cell lines (Fig. 1a), we observed 
membrane localization in the panel of inducible cell lines expressing EGFP-R11.1.6, but not the 
EGFP-YW1 control (Fig. 2a). Specific binding to Ras was confirmed by co-
immunoprecipitation, showing that the cell lines induced to express EGFP-R11.1.6 pull down 
Ras while those expressing EGFP-YW1 do not (Fig. 2b). Having confirmed binding of Ras by 
R11.1.6, we next investigated its effects on downstream signaling, probing for phosphorylation 
of ERK 48 hours following induction of expression (Fig. 2c). Again, we failed to observe any 
inhibition of signaling in response to R11.1.6-mediated Ras antagonism, even at the highest 
concentrations of doxycycline. 
Mathematical model of competitive binding of Ras by R11.1.6 and Raf 
 In an effort to try to understand the lack of signaling inhibition, we developed a simple 
mathematical model to describe the system in which R11.1.6 competes with downstream effector 
proteins for binding of K-Ras (Fig. 3a and Supplementary Fig. S4). For our analysis, we define 
Raf as the model downstream effector since it has the highest affinity for K-Ras, in the double-
digit nanomolar range (22) (compared to low micromolar affinity for PI3K (23,24) and RalGDS 
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(25)), and therefore is the greatest competitor for R11.1.6 binding. We then utilized this model to 
evaluate the feasibility of R11.1.6 inhibiting a significant portion of the K-Ras – Raf complexes 
that drive downstream signaling. 
 To determine the degree of inhibition possible as predicted by our model, we needed to 
quantify the number of copies of EGFP-R11.1.6 expressed by the cells upon induction with 
doxycycline. Quantification of fluorescence yielded an average across all cell lines of 1,300,000 
molecules of EGFP-R11.1.6 per cell (Fig. 3b and Supplementary Fig. S5a), which we confirmed 
by also quantifying based on quantitative western blots (Supplementary Fig. S5b,c). 
 Rather than defining the degree of inhibition as the fraction of K-Ras molecules occupied 
by R11.1.6 (Supplementary Fig. S6a), we normalized the number of K-Ras – Raf complexes that 
form in the presence of a given number of R11.1.6 molecules to the number that form if no 
inhibitor is present and defined this as the fraction of complexes that remain intact 
(Supplementary Fig. S6b,c). From this we then calculated the fraction of complexes that are 
inhibited by R11.1.6 (Supplementary Fig. S6d). Simulation over a range of Raf and R11.1.6 
numbers per cell, with the number of K-Ras molecules held constant at 10
5
 per cell (26), yields a 
heatmap of R11.1.6-mediated inhibition of K-Ras – Raf complex formation (Fig. 3c). At 
approximately 10
6
 copies of EGFP-R11.1.6 per cell and 10
4
 copies of Raf (26), our model 
predicts only 16% inhibition of the K-Ras – Raf complexes that would otherwise form. This then 
could explain our negative results for signal inhibition with both the constitutively expressing 
and inducible cell lines, where we observed membrane localization of R11.1.6 (Fig. 1a and 2a) 
and were able to co-immunoprecipitate Ras (Fig. 2b) but failed to see signaling inhibition at the 
pERK level (Fig. 1b and 2c). We postulate that the binding of R11.1.6 to Ras was sufficient to 
detect in our assays but perhaps insufficient to alter signaling.  
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 Of course, no mathematical model can prove a hypothesis to be correct - it is simply a 
way to test for consistency of particular mechanisms with available data.  Our purpose in 
constructing the presented model is to determine whether the previously demonstrated (27-31) 
membrane localization of Ras effectors such as Raf are sufficient to result in incomplete 
competitive antagonism by R11.1.6.  Comparing antagonism in the presence (Figure 3C) or 
absence (Figure S7) of this Raf localization effect, it is clear that our data are consistent with 
such a hypothesis for a wide range of potential Raf and R11.1.6 concentrations. 
Modeling of the MAPK cascade has shown ERK to be ultrasensitive in its stimulus-
response curve (32). Furthermore, pERK and pAKT have both been shown to be highly sensitive 
to upstream EGF stimulation, with significant signal amplification measured in response to 
minimal input (33). Since Ras-driven signaling is amplified as the cascade proceeds, we propose 
that inhibition of the upstream input be near-complete to observe detectable changes 
downstream. The partial inhibition predicted for R11.1.6 by our simulations therefore would not 
suffice, which is consistent with our cell-line-based data. 
 
Discussion 
We previously described the engineering and characterization of R11.1.6, a high-affinity 
protein antagonist of K-Ras – Raf interaction (16). In this work, we utilized R11.1.6 as a 
genetically encoded tool to evaluate the effects of Raf-competitive Ras antagonism in a panel of 
human cancer cell lines and found that despite measurable binding to endogenous Ras, R11.1.6 
fails to inhibit signaling through both the MAPK and PI3K pathways. We developed a simple 
mathematical model describing the competition for Ras binding between R11.1.6 and 
downstream effector Raf and predicted that at the level of cytoplasmic R11.1.6 expression 
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attained in our stable cell lines, only 16% inhibition of the K-Ras – Raf complexes that drive 
signaling may be achieved. 
While our model can help explain the absence of R11.1.6-mediated signaling inhibition 
that we observed, it should be noted that the simulation is strongly dependent on the adjustment 
of K-Ras – Raf binding made to account for the high local concentration of Raf (Supplementary 
Fig. 4b). Upon activation of Ras, either due to extracellular stimuli or mutation, Raf is recruited 
to the plasma membrane (27-31), its local concentration significantly increases, driving 
interaction with Ras and initiation of downstream signaling. It has been shown that 1,000-fold 
increases in local concentration of factors such as Sos are achieved due to membrane 
localization, and that these increases drive Ras signaling (34). So in our model, we approximated 
the impact of Raf localization by adjusting the on-rate (kon,Raf) for the second binding event in 
bivalent binding at a surface (35) while assuming the off-rate (koff,Raf) is unchanged. This 
effective on-rate ultimately determines the degree of inhibition that can be achieved, which in the 
absence of Raf localization would be approximately 97% (Supplementary Fig. S7). Our model 
therefore suggests that the special feature of a very high local concentration of native ligand may 
make the pharmacological objective of competitive antagonism challenging.    
Our observations propose that Raf-competitive Ras antagonism may be difficult, and 
while several small molecule and protein-based inhibitors have been shown to exert effects on 
Ras-driven signaling and proliferation, these do not necessarily conflict with our conclusions 
here. Small molecules that directly block interaction of Ras with Raf bind with weak affinity and 
exert their effects at concentrations in the hundreds of micromolar range (7-9). Such high 
concentrations may translate into drug molecules on the order of 10
7
 per cell, at which point our 
simulation predicts near complete inhibition (Fig. 3c). Our own characterization of R11.1.6 in 
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the model HEK 293T system showed significant signaling inhibition, but only when plasmid 
encoding R11.1.6 was transfected at greater amounts than plasmid encoding K-Ras G12D (16). 
A recent self-internalizing antibody that blocks Ras interaction with downstream effector 
proteins showed efficacy in both cell-based assays and murine xenograft models (14). Again, 
micromolar concentrations were required to observe effects, the bivalent IgG format may 
increase avidity significantly, and it is possible the antibody constant region contributed function 
via intracellular Fc receptors, analogous to that observed for intracellular antibody-bound 
pathogens (36). Finally, a single antibody VH domain engineered to bind mutant H-Ras was 
shown to compete with effector proteins, but only exhibited efficacy when a membrane-
localizing peptide was appended (12). 
Pharmacological inhibition of Ras-driven tumors continues to be challenging, and while 
significant progress has been made over the years, the Ras problem is far from solved. Our 
findings may help shed light on a particular difficulty of interrupting this signaling axis and the 
potential hurdles that must be overcome in competitive Ras antagonism. Perhaps alternative 
approaches, such as allosteric antagonists (13), covalent allele-specific G12C inhibitors (37,38), 
or immunotherapy (39), are likely to have greater chances of success given this possible 
fundamental issue.   
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Table 1. Human cancer cell lines for inducible EGFP-R11.1.6/YW1 expression. 
Cell Line Tissue K-Ras 
A431 skin WT 
HT-29 colon WT 
SW48 WT colon WT 
LS180 colon G12D 
HPAF-II pancreas G12D 
SW48 G12D colon G12D 
Calu-1 lung G12C 
NCI-H23 lung G12C 
SW48 G12C colon G12C 
SW48 G12V colon G12V 
PA-TU-8902 pancreas G12V 
PA-TU-8988T pancreas G12V 
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Figure 1. Constitutive intracellular expression of R11.1.6 has no apparent effect on cancer 
cell signaling and proliferation. a, Fluorescence microscopy of human cancer cell lines HT-29 
(K-Ras WT), LS180 (K-Ras G12D), and HPAF-II (K-Ras G12D) transduced to constitutively 
express EGFP-tagged R11.1.6, EGFP-tagged control YW1, or EGFP only. Scale bars are 30 μm. 
b, Western blots probing phosphorylation of endogenous MEK (pMEK), ERK (pERK), and 
AKT at Ser473 (pAKT) in human cancer cell lines A431 (K-Ras WT), HT-29 (K-Ras WT), 
LS180 (K-Ras G12D), and HPAF-II (K-Ras G12D), constitutively expressing R11.1.6, YW1, or 
EGFP. c, Proliferation, as measured by absorbance at 440 nm, of cell lines as in a over 72 hours.     
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Figure 2. Inducible intracellular expression of R11.1.6 has no effect on ERK 
phosphorylation in cancer cell lines. a, Fluorescence microscopy of the human cancer cell lines 
listed in Table 1, induced with doxycycline for 48 hours to express EGFP-tagged R11.1.6 or 
EGFP-tagged control YW1. Scale bars are 30 μm. b, Co-immunoprecipitation of Ras with 
EGFP-tagged R11.1.6/YW1 in inducible cell lines after 48 hours of induction with doxycycline. 
IP, immunoprecipitation; WCL, whole cell lysate. c, Western blots probing phosphorylation of 
endogenous ERK in inducible cell lines after 48 hours of induction with doxycycline. Increasing 
final doxycycline concentrations shown are 125, 250, 500, 1000, and 2000 ng/mL.        
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Figure 3. Model of Raf-competitive K-Ras antagonism by R11.1.6 offers insight into lack of 
effects on cancer cells. a, Schematic of mathematical model using mass action kinetics to 
describe the competitive binding of K-Ras by R11.1.6 and downstream effector Raf. b, 
Quantification of the total number of copies of EGFP-tagged R11.1.6 per cell in each of the 
inducible cancer cell lines. Each point represents the average of n = 3 replicates. Individual cell 
line quantifications are given in Supplementary Fig. S5a. c, Model-derived heatmap depicting 
the fraction of inhibition of K-Ras – Raf complex formation by R11.1.6 as a function of the total 
number of Raf and R11.1.6 molecules per cell. Simulation held the number of K-Ras molecules 
constant at 10
5
 molecules per cell. Dotted lines indicate the average number of EGFP-R11.1.6 
molecules per cell as measured in b and the number of Raf molecules per cell as presented in the 
literature (26). 
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